Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection
{{output}}
Immunocompromised people are at high risk of prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and progression to severe coronavirus disease 2019 (COVID-19). However, the efficacy of late-onset direct-acting antiviral (DAA) thera... ...
